Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea

Hong, Ki Ho; Lee, Sangwon; Kim, Taek Soo; Huh, Hee Jae; Lee, Jaehyeon; Kim, So Yeon; Park, Jae Sun; Kim, Gab Jung; Sung, Heungsup; Roh, Kyoung Ho; Kim, Jae‐Seok; Kim, Hyo Soo; Lee, Seung Tae; Seong, Moon Woo; Ryoo, Nam Hee; Lee, Hyukmin; Kwon, Gye Cheol; Yoo, Cheon-Kwon

doi:10.3343/alm.2020.40.5.351

Cited by 332 publications

(350 citation statements)

References 7 publications

Supporting

Mentioning

306

Contrasting

Unclassified

Order By: Relevance

“…Suspected cases of COVID-19 and TB show similar fever and/or respiratory symptoms (di cult respiration, coughing, chest pain, etc.). COVID-19 RT-PCR should be done in real-time for differential diagnosis of cases with unknown respiratory syndromes such as PTB [52]. Due to poor outcomes among COVID-19/HIV/TB or COVID-19/TB co-infections, we recommend COVID-19 real-time RT-PCR should be coupled with Xpert MTB/RIF assay.…”

Section: Tb Diagnosis In Covid-19/hiv Co-infectionmentioning

confidence: 99%

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

Tamuzi

Birhanu

Shumba³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The triple burden of COVID-19, tuberculosis and human immunodeficiency virus is one of the major global health challenges of the 21st century. In high burden HIV/TB countries, the spread of COVID-19 among people living with HIV is a well-founded concern. A thorough understanding of HIV/TB and COVID-19 pandemics is important as the three diseases interact. This may clarify HIV/TB/COVID-19 as a newly related field. However, several gaps remain in the knowledge of the burden of COVID-19 on patients with TB and HIV. This study was conducted to review different studies on SARS-CoV, MERS-CoV or COVID-19 associated with HIV/TB co-infection or only TB, to understand the interactions between HIV, TB and COVID-19 and its implications on the burden of the COVID-19 among HIV/TB co-infected or TB patients, screening algorithm and clinical management.Methods: We conducted an electronic search of potentially eligible studies published in English in the Cochrane Controlled Register of Trials, PubMed, Medrxiv, Google scholar and Clinical Trials Registry databases. We included case studies, case series and observational studies published between January, 2002 and July, 2020 in which SARS-CoV, MERS-CoV and COVID-19 co-infected to HIV/TB or TB in adults. We screened titles, abstracts and full articles for eligibility. Descriptive and meta-analysis were done and results have been presented in graphs and tables.Results: After removing 95 duplicates, 58 out of 437 articles were assessed for eligibility, of which 14 studies were included for descriptive analysis and seven studies were included in the meta-analysis. Compared to the descriptive analysis, the meta-analysis showed strong evidence that current TB exposure was high-risk COVID-19 group (OR 1.67, 95% CI 1.06-2.65, P= 0.03). The pooled of COVID-19/TB severity rate increased from OR 4.50 (95% CI 1.12-18.10, P=0.03), the recovery rate was high among COVID-19 compared to COVID-19/TB irrespective of HIV status (OR 2.23, 95% CI 1.83-2.74, P < 0.001) and the mortality was reduced among non-TB group (P<0.001).Conclusion: In summary, TB was a risk factor for COVID-19 both in terms of severity and mortality irrespective of HIV status. Structured diagnostic algorithms and clinical management are suggested to improve COVID-19/HIV/TB or COVID-19/TB co-infections outcomes.

show abstract

Section: Tb Diagnosis In Covid-19/hiv Co-infectionmentioning

confidence: 99%

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

Tamuzi

Birhanu

Shumba³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…43 In South Korea, COVID-19 diagnostic tests, mostly SARS-CoV-2 real-time polymerase chain reaction (RT-PCR), are applied to persons who have been in contact with COVID-19 positive patients or to those with symptoms suspicious of COVID-19. 44,45 We de ned the con rmation of COVID-19 using the con rmation code provided by the HIRA based on the KCDC data. 3 Information on the demographics of participants, type of insurance (health insurance and medical aid), and comorbidities was based on claims codes.…”

Section: Methodsmentioning

confidence: 99%

Impact of comorbidity burden on mortality in patients with COVID-19: a retrospective analysis of the Korean health insurance database

Cho

Yoon

Lee

2020

Preprint

View full text Add to dashboard Cite

We aimed to investigate the impact of comorbidity burden on mortality in patients with COVID-19. We analyzed the COVID-19 data from the nationwide health insurance claims of South Korea. Data on demographic characteristics, comorbidities, and mortality records of patients with COVID-19 were extracted from the database. The odds ratios of mortality according to comorbidities in patients with COVID-19 with and without adjustment for age and sex were calculated. The predictive value of the original Charlson comorbidity index (CCI) and the age-adjusted CCI (ACCI) for mortality in patients with COVID-19 were investigated using the receiver operating characteristic (ROC) curve analysis. Among 7,590 patients with COVID-19, 227 (3.0%) had died. After age and sex adjustment, hypertension, diabetes mellitus, congestive heart failure, dementia, chronic pulmonary disease, liver, renal, and cancer were significant risk factors for mortality. The ROC curve analysis showed that ACCI threshold ≥4 yielded the best cut-off point for predicting mortality (area under the ROC 0.92; 95% CI, 0.91–0.94). Our study revealed multiple risk factors that were associated with mortality in patients with COVID-19. The high predictive power of the ACCI for mortality in our results could support the importance of old age and comorbidities in the severity of COVID-19.

show abstract

“…The virus, a novel member of the coronavirus family, was later named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Virus Classification Commission, and the disease was termed COVID-19 by WHO on February 11, 2020. [1][2][3][4] Before COVID-19, the other Coronavirusmediated outbreaks included severe acute respiratory syndrome (SARS-CoV) and middle east respiratory syndrome (MERS-CoV). The disease had a significant spread in various countries of the world due to the superspreading nature of the infection, with the WHO declaring it as a global pandemic on March 11, 2020.…”

Section: Introductionmentioning

confidence: 99%

Association of Comorbidities with Coronavirus Disease 2019: A Review

Mitra

Suri

Goyal

et al. 2020

Annals of the National Academy of Medical Sciences (India)

View full text Add to dashboard Cite

AbstractThe novel Coronavirus disease 2019 (COVID-19) pandemic started with few cases of pneumonia of unknown origin in Wuhan, China. It has now become one of the significant public health emergencies of all time. Within 5 months of its existence, it has led to a significant impact on national and international policies. Apart from being a medical emergency, it is also affecting the global economy, and without proper measures, it may have severely impact the socioeconomic statuses of individuals. It has profoundly challenged the healthcare infrastructure, particularly in low- and middle-income nations. Every nation is trying to safeguard its population and the health workers as adequately as possible. While we still wait for the development of an absolute cure in the form of a vaccine, preventive measures have taken the lead in reducing the disease spread and breaking the chain of transmission. The knowledge gained from the clinical characteristics of patients has suggested markers or comorbid conditions that may aid in the risk assessment. This narrative review aims to provide an update on SARS-CoV-2, the causative virus of COVID-19, its pathogenesis, the clinical and laboratory features, and its association with several comorbid conditions that may influence the prognosis of this disease.

show abstract

Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea

Cited by 332 publications

References 7 publications

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

Impact of comorbidity burden on mortality in patients with COVID-19: a retrospective analysis of the Korean health insurance database

Association of Comorbidities with Coronavirus Disease 2019: A Review

Contact Info

Product

Resources

About